Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
Stopped early
Conditions studied: Prostatic Neoplasms
In brief
Primary Objective: * Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: * Describe treatment patterns * Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to others * Describe economic and patient-reported outcomes
Key facts
- Study ID
- NCT01076751
- Run by
- Sanofi
- People needed
- 82
- Starts
- 2010-02-01
- Expected to finish
- 2010-10-01
- Last updated by the study team
- 2011-02-14
Who can join
Age: any. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Patients with CRPC progressing during the course of first line docetaxel-based chemotherapy or after at least 3 cycles (equivalent to 225mg/m2) of first line docetaxel-based chemotherapy
- Patient who have given their written consent
You may not qualify if…
- Current participation in a clinical trial for the second-line treatment of prostate cancer
- Patients having received less than 3 cycles of first line docetaxel-based chemotherapy and discontinued for a reason other than disease progression or toxicity
- Patients having already started a second line treatment
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Where it is running
- Sanofi-Aventis Administrative Office — Bridgewater, New Jersey, United States
- Sanofi-Aventis Administrative Office — Paris, France
- Sanofi-Aventis Administrative Office — Frankfurt, Germany
- Sanofi-Aventis Administrative Office — Barcelona, Spain
- Sanofi-Aventis Administrative Office — Guildford Surrey, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.